证券日报网讯 1月27日，万孚生物在互动平台回答投资者提问时表示，公司关于分子诊断最新的仪器为 全自动核酸提纯及实时荧光PCR分析系统WonNova1600（国械注准20253222465），WonNova1600突破 了传统PCR在空间、人力和效率上的多重边界，赋能医院更快、更准、更轻松应对各类挑战。 （编辑 丛可心） ...

证券日报网讯1月27日，万孚生物（300482）在互动平台回答投资者提问时表示，公司将持续关注渠道 开拓业务进展，根据市场需求动态调整产品推广力度。 ...

Core Viewpoint - Weigao Orthopedics announced that the signing ceremony for its surgical robot, developed by Beijing Weigao Smart Technology Co., Ltd., at the 2025 COA conference did not result in actual sales, and the company is not included in the consolidated financial statements of the listed company [1] Group 1: Product Development and Technology - The orthopedic robot utilizes AI three-dimensional modeling, automatically picks feature points, and employs optimized matching algorithms, providing strong end-effector power that aligns closely with clinical surgical needs [1] - The company is enhancing market integration with its group orthopedic surgical robot company to promote product education and hospital deployment [1] - The five-in-one ultrasonic bone power system, a core technology product acquired from Jiesibai'er Company, is expected to receive certification in the second half of 2025, integrating five major functions: ultrasonic bone knife, power, milling, perfusion pump, and negative pressure absorption [1] Group 2: Financial and Corporate Structure - As of the end of 2025, the sales revenue from the five-in-one ultrasonic bone power system will not be reflected in the listed company's annual report due to the incomplete equity change of Jiesibai'er [1]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The recent policy issued by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical and biotechnology index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.1 percentage points [11] - The report suggests focusing on high-quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin, as the pharmaceutical commercial sector is expected to see improved performance due to favorable policies [33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Among sub-sectors, pharmaceutical commerce rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] - The top five A-share stocks in the industry this week included *ST Changyao (+70.37%) and Hualan Biological Engineering (+32.21%) [22] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and industry structure [28] - A loan interest subsidy policy for small and micro enterprises in the pharmaceutical sector was announced, aimed at encouraging investment in manufacturing [28] Company Announcements - Significant announcements include the resignation of executives at various companies and performance forecasts indicating potential losses for some firms due to price reductions and demand declines [36]

公司始终坚持战略变革延续，聚焦数字慢病管理领域，推动公司中长期战略规划与年度经营计划实施落 地。公司 2025 年度预计归属于上市公司股东的净利润较上年同期增长32.00%至 38.52%。报告期内，公 司持续优化现有业务、产品结构，积极提升高盈利客户占比，带动整体综合毛利率实现稳步提升。通过 内部运营的精细化管理，全面持续推进降本增效、优化资源配置，推动经营效率持续性改善。同时通过 优化应收账款管理机制、加强存货管理提高资产运营效率，最终实现利润的稳步增长。报告期内公司应 收账款周转率和存货周转率等运营能力指标得到有效提升，公司整体盈利水平显著提升。报告期内，非 经常性损益对公司净利润的影响金额预计为人民币630 万元。 格隆汇1月27日丨乐心医疗(300562.SZ)公布，预计2025年归属于上市公司股东的净利润8,100万元～ 8,500万元，比上年同期增长32.00%～38.52%，扣除非经常性损益后的净利润7,500万元～7,900万元，比 上年同期增长33.98%～41.13%。 ...

开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 证券之星消息，截至2026年1月27日收盘，开立医疗(300633)报收于28.3元，下跌1.97%，换手率 0.81%，成交量3.5万手，成交额9904.12万元。 1月27日的资金流向数据方面，主力资金净流入358.38万元，占总成交额3.62%，游资资金净流出127.24 万元，占总成交额1.28%，散户资金净流出231.13万元，占总成交额2.33%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有8家机构给出 ...

Core Viewpoint - The company expects a net profit attributable to shareholders of 15 million to 16 million yuan for the full year of 2025, driven by growth in the OTC hearing aid market and successful integration of acquired technology [1] Group 1: Performance Forecast - The company anticipates a year-on-year increase in net profit attributable to shareholders for 2025, primarily due to sustained demand in the U.S. OTC market and enhanced operational strategies [1] - The company has strengthened partnerships with key brand clients, leading to increased orders and revenue from brand partners [1] - The company has accelerated the development of its own brand channels, resulting in significant revenue growth from proprietary products [1] Group 2: Recent Financial Results - For the first three quarters of 2025, the company reported a main operating revenue of 196 million yuan, an increase of 82.44% year-on-year [2] - The net profit attributable to shareholders for the same period reached approximately 17.63 million yuan, reflecting a year-on-year increase of 565.54% [2] - The third quarter alone saw a main operating revenue of 82.22 million yuan, up 87.17% year-on-year, with a net profit of approximately 991.96 thousand yuan, marking a staggering increase of 1162.04% [2]

近年来，北京在促进创新药械推广应用、促进"人工智能+医疗健康"融合创新等方面成果颇丰。不过，在临床领域，创新药械如何走向临床"最后一公里"仍 是现阶段部分疾病诊疗面临的难题。在政协北京市第十四届委员会第四次会议期间，来自医药卫生界的市政协委员、首都医科大学附属首都儿童医学中心新 生儿外科首席专家马立霜在接受北京商报记者采访时建议，在坚持集采政策总体框架下，为那些针对特殊人群（如新生儿）、临床急需且技术优势明显的国 产创新设备，开辟一条更具弹性的准入与采购通道，让国产优质创新资源能第一时间服务患者。 AI助力提升产前诊断准确性与可及性 在目前我国出生人口持续下降的大背景下，广大孕产妇及家庭对于健康孕育的要求在不断提高。 先天性食道闭锁、肛门闭锁、膈疝……这些疾病意味着孩子出生后可能无法正常进食、排便或呼吸，若不及时进行外科手术干预，危重者将面临生命危险。 马立霜作为一名在临床工作超30年的临床医生，常年深耕于新生儿先天畸形这一疾病领域。 对于"小小孩"胎儿新生儿先天性畸形疾病的诊断主要依靠产前超声检查。由于胎儿身体小、内部结构复杂，病变部位难以确定，使得早期诊断和准确分型具 有一定的困难，出生缺陷结构畸形产前诊 ...

证券日报网讯1月27日，易瑞生物（300942）在互动平台回答投资者提问时表示，公司已战略性收缩体 外诊断业务，暂无尼帕病毒的相关检测产品。目前公司专注于食品安全检测业务的稳步发展，并大力拓 展动物诊断业务。 ...

证券日报网讯 1月27日，山外山发布公告称，公司分别于2025年12月3日召开第二届审计委员会第十三 次会议和第三届董事会第二十二次会议，2025年12月22日召开2025年第四次临时股东会审议通过了《关 于部分募投项目调整及新增募投项目的议案》，同意公司本次部分募投项目调整及新增募投项目事项， 同时为确保募集资金使用安全，拟对山外山、重庆天外天生物技术有限公司（简称"天外天"）分别设立 募集资金专项账户，并与保荐人和存放募集资金的银行签署募集资金专户存储监管协议，且由董事会授 权管理层全权办理与本次募集资金专项账户相关后续事宜。为规范本次募集资金的存放、使用与管理， 提高资金使用效率，根据相关法律法规、规范性文件的规定，公司及全资子公司天外天、保荐人西部证 券股份有限公司、招商银行股份有限公司重庆分行签署了《募集资金三方监管协议》。 （编辑 任世碧） ...